Veera Raghava Chowdary Palacharla

Absorption, Distribution, Metabolism, Excretion (ADME), Drug-drug interaction potential and Prediction of Human Pharmacokinetics of SUVN-G3031, a Novel Histamine 3 Receptor (H3R) inverse agonist in Clinical development for the treatment of Narcolepsy.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A definite measure of occupancy exposures, seeking with non-radiolabeled in vivo 5-HT2A receptor occupancy and in vitro free fractions

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2018, Journal of receptor and signal transduction research.

Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

A. Atri, R. Nirogi, J. Cummings, 2022, Alzheimer's & dementia.

Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2022, Clinical Drug Investigation.

Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2022, Psychopharmacology.

The use of inactivated brain homogenate to determine the in vitro fraction unbound in brain for unstable compounds

R. Nirogi, G. Bhyrapuneni, Arunkumar Manoharan, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses

Abdul Rasheed Mohammed, R. Nirogi, K. Mudigonda, 2020, Clinical Drug Investigation.

First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2021, Clinical Drug Investigation.

Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling.

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2023, European journal of pharmacology.

SUVN-502, POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST: PROOF-OF-CONCEPT STUDY DESIGN IN MODERATE ALZHEIMER’S DISEASE PATIENTS

R. Nirogi, K. Mudigonda, A. Shinde, 2016, Alzheimer's & Dementia.